首页> 美国卫生研究院文献>Acta Neuropathologica Communications >Hippocampal administration of chondroitinase ABC increases plaque-adjacent synaptic marker and diminishes amyloid burden in aged APPswe/PS1dE9 mice
【2h】

Hippocampal administration of chondroitinase ABC increases plaque-adjacent synaptic marker and diminishes amyloid burden in aged APPswe/PS1dE9 mice

机译:海马软骨素酶ABC的使用可增加老年APPswe / PS1dE9小鼠的斑块邻近突触标记并减轻淀粉样蛋白负荷

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

IntroductionSubstantial data has shown that the lectican group of chondroitin sulfate proteoglycans are involved in inhibition of axonal plasticity in response to injury in the central nervous system. Increasing evidence indicates that lecticans may also play a role in synaptic plasticity related to memory, especially associated with aging. A recent study has shown that lectican expression is elevated at a young age in the APPswe/PS1dE9 mouse model and Alzheimer’s disease (AD) and hippocampal treatment with chondroitinase ABC reversed a loss of contextual fear memory and restored long-term potentiation. The purpose of this study was to examine the presence of a synaptic lectican in AD tissue, determine if amyloid-β (Aβ) binds to lecticans purified from brain tissue, and examine how treatment of the same AD model with chondroitinase ABC would influence plaque burden and the density of the synaptic marker synaptophysin around plaques.
机译:引言大量数据表明,硫酸软骨素蛋白聚糖的lectican组参与了对中枢神经系统损伤后轴突可塑性的抑制作用。越来越多的证据表明,lecticans也可能在与记忆有关的突触可塑性中发挥作用,尤其是与衰老有关。最近的一项研究表明,APPswe / PS1dE9小鼠模型中,lectican的表达在年轻时就升高了,而阿尔茨海默氏病(AD)和软骨素酶ABC的海马治疗逆转了上下文恐惧记忆的丧失,并恢复了长期的增强作用。这项研究的目的是检查AD组织中突触性lectican的存在,确定淀粉样蛋白-β(Aβ)是否与从脑组织中纯化的lecticans结合,并检查用软骨素酶ABC治疗同一AD模型如何影响斑块负担和斑块周围的突触标记突触素的密度。

著录项

相似文献

  • 外文文献
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号